Influence of Genotype on Structural Atrial Abnormalities and Atrial Fibrillation or Flutter in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Structural Atrial Involvement in ARVD/C Introduction Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is associated with desmosomal mutations. Although desmosomal disruption affects both ventricles and atria, little is known about atrial involvement in ARVD/C. Objective To describe...
Saved in:
Published in | Journal of cardiovascular electrophysiology Vol. 27; no. 12; pp. 1420 - 1428 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.12.2016
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1045-3873 1540-8167 1540-8167 |
DOI | 10.1111/jce.13094 |
Cover
Summary: | Structural Atrial Involvement in ARVD/C
Introduction
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is associated with desmosomal mutations. Although desmosomal disruption affects both ventricles and atria, little is known about atrial involvement in ARVD/C.
Objective
To describe the extent and clinical significance of structural atrial involvement and atrial arrhythmias (AA) in ARVD/C stratified by genotype.
Methods
We included 71 patients who met ARVD/C Task Force Criteria and underwent cardiac magnetic resonance (CMR) imaging and molecular genetic analysis. Indexed atrial end‐diastolic volume and area‐length‐ejection‐fraction (ALEF) were evaluated on CMR and compared to controls with idiopathic right ventricular outflow tract tachycardia (n = 40). The primary outcome was occurrence of AA (atrial fibrillation or atrial flutter) during follow‐up, recorded by 12‐lead ECG, Holter monitoring or implantable cardioverter defibrillator (ICD) interrogation.
Results
Patients harbored a desmosomal plakophilin‐2 (PKP2) (n = 37) or nondesmosomal phospholamban (PLN) (n = 14) mutation. In 20 subjects, no pathogenic mutation was identified. Compared to controls, right atrial (RA) volumes were reduced in PKP2 (P = 0.002) and comparable in PLN (P = 0.441) mutation carriers. In patients with no mutation identified, RA (P = 0.011) and left atrial (P = 0.034) volumes were increased. Bi‐atrial ALEF showed no significant difference between the groups. AA were experienced by 27% of patients and occurred equally among PKP2 (30%) and no mutation identified patients (30%), but less among PLN mutation carriers (14%).
Conclusion
Genotype influences atrial volume and occurrence of AA in ARVD/C. While the incidence of AA is similar in PKP2 mutation carriers and patients with no mutation identified, PKP2 mutation carriers have significantly smaller atria. This suggests a different arrhythmogenic mechanism. |
---|---|
Bibliography: | ark:/67375/WNG-Z917M243-5 Table S1. Pathogenic Mutations Identified in ARVD/C Patients. No. = number; PKP2 = plakophilin-2; PLN = phospholamban.Table S2. ARVD/C Patients Stratified in Probands and Family Members. Mean values ± standard deviation; number (%); *Fisher exact test; AA = atrial arrhythmias; ICD = implantable cardioverter defibrillator. Dutch Heart Association - No. 2015T058 istex:59562C9C60DDA53D015366EE1100865FC06B964E Heart Rhythm Society: Clinical Research Award in Honor of Mark Josephson and Hein Wellens ArticleID:JCE13094 Disclosures: None. This work was supported by the Dutch Heart Association (2015T058 to Dr. Te Riele). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 1045-3873 1540-8167 1540-8167 |
DOI: | 10.1111/jce.13094 |